BiotechTube
GeneCentric Therapeutics

GeneCentric Therapeutics

Durham, United States· Est.
genecentric.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $27.5M

Overview

GeneCentric Therapeutics is a private, commercial-stage diagnostics company pioneering integrated liquid biopsy solutions for precision oncology. Its core innovation is the GenomicsNext™ platform, powered by proprietary ExpressCT™ technology, which infers gene expression from standard ctDNA sequencing data, adding a critical new dimension to liquid biopsies. The company has a commercial product, PurIST®, for pancreatic cancer subtyping, and is advancing its platform through strategic collaborations with biopharma and diagnostic partners to enhance drug development and clinical decision-making.

Oncology

Technology Platform

GenomicsNext™ integrated liquid biopsy platform, powered by proprietary ExpressCT™ technology which uses AI and ctDNA fragmentomics to infer gene expression from standard ctDNA sequencing data, enabling simultaneous detection of DNA alterations and gene expression profiles from a single blood draw.

Funding History

3
Total raised:$27.5M
Series B$15M
Series A$10M
Seed$2.5M

Opportunities

The primary opportunity lies in addressing the significant gap in liquid biopsy by adding the critical dimension of gene expression to standard DNA testing, enabling more complete tumor profiling.
This creates value in clinical diagnostics for therapy guidance and, more substantially, in pharmaceutical R&D for patient stratification, biomarker discovery, and companion diagnostic development through strategic partnerships.

Risk Factors

Key risks include the need for extensive clinical validation to prove the utility and accuracy of inferring gene expression from ctDNA across diverse cancers and settings.
The company also faces intense competition from larger, well-funded liquid biopsy players and is dependent on the success of its partnership-driven business model for growth and revenue.

Competitive Landscape

GeneCentric competes in the crowded liquid biopsy market dominated by large players like Guardant Health and Foundation Medicine that focus heavily on DNA sequencing. Its key differentiation is the proprietary integration of gene expression data from ctDNA, a feature not yet widely commercialized. It faces competition from companies also exploring multi-omic approaches, including those analyzing cfRNA or fragmentomics, but aims to lead with its specific AI-powered ExpressCT technology.

More companies in Diagnostics & Precision Medicine →More companies in United States →